These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 10181679)

  • 21. Prescription drug pricing: the consumer perspective.
    Searing A
    N C Med J; 2003; 64(6):300-2. PubMed ID: 14983625
    [No Abstract]   [Full Text] [Related]  

  • 22. A cost-effectiveness approach to drug subsidy and pricing in Australia.
    Birkett DJ; Mitchell AS; McManus P
    Health Aff (Millwood); 2001; 20(3):104-14. PubMed ID: 11585158
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Australia-United States Free Trade Agreement and the Australian Pharmaceutical Benefits Scheme.
    Sainsbury P
    Yale J Health Policy Law Ethics; 2004; 4(2):387-99. PubMed ID: 15536920
    [No Abstract]   [Full Text] [Related]  

  • 24. Economic analysis as an aid to subsidisation decisions: the development of Australian guidelines for pharmaceuticals.
    Henry D
    Pharmacoeconomics; 1992 Jan; 1(1):54-67. PubMed ID: 10147039
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmaceuticals issue brief: managed care drug formularies: year end report-2003.
    MacEachern L
    Issue Brief Health Policy Track Serv; 2003 Dec; ():1-8. PubMed ID: 14969259
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England.
    Mansfield SJ
    Aust Health Rev; 2014 Feb; 38(1):6-15. PubMed ID: 24480618
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Are Australians able to access new medicines on the pharmaceutical benefits scheme in a more or less timely manner? An analysis of pharmaceutical benefits advisory committee recommendations, 1999-2003.
    Wonder MJ; Neville AM; Parsons R
    Value Health; 2006; 9(4):205-12. PubMed ID: 16903989
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Australian pharmaceutical policy: price control, equity, and drug innovation in Australia.
    Doran E; Alexander Henry D
    J Public Health Policy; 2008 Apr; 29(1):106-20. PubMed ID: 18368023
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Precipitating factors for pharmaceutical firms.
    McCarthy R
    State Health Care Am; 1997; ():39-43. PubMed ID: 10168083
    [No Abstract]   [Full Text] [Related]  

  • 30. Does generic entry lower the prices paid for pharmaceuticals in Australia? A comparison before and after the introduction of the mandatory price-reduction policy.
    Spinks J; Chen G; Donovan L
    Aust Health Rev; 2013 Nov; 37(5):675-81. PubMed ID: 24160374
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The pharmaceutical situation in the Philippines.
    Hartigan-Go K
    Aust Health Rev; 2001; 24(2):25-31. PubMed ID: 11496467
    [No Abstract]   [Full Text] [Related]  

  • 32. The effect of pharmaceutical benefits managers: is it being evaluated?
    Schulman KA; Rubenstein LE; Abernethy DR; Seils DM; Sulmasy DP
    Ann Intern Med; 1996 May; 124(10):906-13. PubMed ID: 8610921
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmaceutical cost containment and innovation in the United States.
    Kane NM
    Health Policy; 1997 Sep; 41 Suppl():S71-89. PubMed ID: 10174475
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of Japanese government policy on hospital pharmaceutical profit levels.
    Oliver AJ; Ikegami N; Ikeda S
    J Health Serv Res Policy; 1999 Jan; 4(1):27-32. PubMed ID: 10345563
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of the Minimum Pricing Policy and introduction of brand (generic) substitution into the Pharmaceutical Benefits Scheme in Australia.
    McManus P; Birkett DJ; Dudley J; Stevens A
    Pharmacoepidemiol Drug Saf; 2001; 10(4):295-300. PubMed ID: 11760489
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drugs down under.
    Wonder MJ; Wyber D
    Health Aff (Millwood); 2006; 25(4):1185; author reply 1185-6. PubMed ID: 16835205
    [No Abstract]   [Full Text] [Related]  

  • 37. Barrier to trade or barrier to profit? Why Australia's Pharmaceutical Benefits Scheme worries U.S. drug companies.
    Hamilton C; Lokuge B; Denniss R
    Yale J Health Policy Law Ethics; 2004; 4(2):373-85. PubMed ID: 15536919
    [No Abstract]   [Full Text] [Related]  

  • 38. Support for trials of promising medications through the Pharmaceutical Benefits Scheme. A proposal for a new authority category.
    Glasziou PP
    Med J Aust; 1995 Jan; 162(1):33-6. PubMed ID: 7605432
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Centralized drug review processes: are they fair?
    Mitton CR; McMahon M; Morgan S; Gibson J
    Soc Sci Med; 2006 Jul; 63(1):200-11. PubMed ID: 16427728
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Perspectives. Drug formularies pose legal threat to providers.
    Moskowitz DB
    Faulkner Grays Med Health; 1995 Feb; 49(6):suppl 1-4. PubMed ID: 10139750
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.